I obtained my PhD in Molecular Biology at Imperial College, London, before moving on to postdoctoral positions in Australia.永利皇冠app
My background is in genetics and gene therapy – I first identified the genes required for development of the Drosophila brain and then generated one of the first mouse models of cystic fibrosis with the same mutation as found in humans. This was followed by work on gene therapy for cystic fibrosis in a collaboration between Boehringer Ingelheim and the Medical Research Council (MRC) Human Genetics Unit in Edinburgh.
I joined AstraZeneca as a 团队 Leader in 1997 and since then, have provided support for many drug discovery projects around target identification, validation and reagent generation. I have also been a project leader for several small molecule and biologics project 团队s. In 2002, I became a Principal Scientist and in 2011 moved to Gothenburg where I have led 团队s carrying out target validation and biomarker discovery.
I’m excited by my work – through our experience and great collaborators we have the potential to make real progress in challenging areas of respiratory science.
LEADING BIOSCIENCE 团队
ONE OF THE FIRST TO GENERATE MICE CARRYING A HUMAN CYSTIC FIBROSIS MUTATION
G551D cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages永利皇冠app
Thomas GR, Costelloe EA, Lunn DP et al. J Immunol 2000: 164.7.3870
Rapid simultaneous clong of drug targets from multiple mammalian species永利皇冠app
Jupp R1, Dusanjh PK, Walding A, McHale M, Belfield GP, Delaney SJ. 2006 Jun;34(3):295-303.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.